Side-by-side · Research reference

ChonlutenvsGLP-1 (7-37)

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED8/38 cited

BHuman-MechanisticHUMAN-REVIEWED16/43 cited

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

GLP-1 (7-37)

Incretin Hormone · Native Peptide

~2 minHalf-lifeAlavi 2021 Ding 2017

3297.7 DaMolecular weightAlavi 2021

1922Discovery year

Research use only · IV/SC in experimental settings

01Mechanism of Action

Parameter

Chonluten

GLP-1 (7-37)

Primary target

Bronchial epithelial cells and respiratory mucosa tissue complexes

GLP-1 receptor (class B GPCR)Koole 2015

Pathway

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

GLP-1R activation → cAMP production → PKA signaling → insulin secretion (pancreatic β-cells)Lu 2025 Koole 2015

Downstream effect

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Glucose-dependent insulin release, glucagon suppression, delayed gastric emptying, reduced food intakeLu 2025 Ding 2017

Feedback intact?

—

Yes — physiological secretion and degradation preserved

Origin

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

Endogenous peptide cleaved from proglucagon in intestinal L cells; secreted postprandially

Antibody development

—

02Dosage Protocols

Parameter

Chonluten

GLP-1 (7-37)

Typical protocol dose

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

—

Frequency

Once or twice daily

—

Route

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

—

Evidence basis

In vitro mechanistic

—

Duration

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

—

Clinical validation

None (PubMed indexed)

—

Clinical use

—

None — native GLP-1 not used therapeutically

Engineered analogues (semaglutide, liraglutide) used clinically.Friedman 2024

Research dosing

—

Variable — 0.1–10 nmol/kg in animal models

Used as reference standard for analogue comparison.

Half-life

—

~2 minutes (plasma)Alavi 2021 Ding 2017

Requires continuous infusion for sustained effect.

Modified analogues

—

t½ extended to 13 h (liraglutide), 165 h (semaglutide)

Via DPP-4 resistance + fatty acid acylation.

03Metabolic / Fat Loss Evidence

Parameter

Chonluten

GLP-1 (7-37)

Mechanism

—

GLP-1R activation in hypothalamic satiety centers (arcuate nucleus) reduces food intakeLu 2025

Effect demonstrated with long-acting analogues (liraglutide).Lu 2025

Native GLP-1 efficacy

—

Minimal — rapid degradation prevents sustained appetite suppression

Gastric emptying

—

Delayed in animal models, contributing to satiety

Body weight impact

—

Not observed with native GLP-1 — requires analogue formulations

04Side Effects & Safety

Parameter

Chonluten

GLP-1 (7-37)

Documented adverse events

No published safety data in PubMed-indexed literature

—

Theoretical risks

Peptide hypersensitivity, GI intolerance (uncharacterized)

—

Drug interactions

Unknown — no pharmacokinetic studies available

—

Pregnancy / lactation

No data — avoid

—

Native GLP-1

—

Well-tolerated in research settings; no prolonged exposure data

Hypoglycemia risk

—

Low — insulin secretion is glucose-dependent

Analogue side effects

—

Nausea, vomiting, diarrhea (GLP-1R agonists)

Not applicable to native GLP-1 due to non-therapeutic use.

GLP-1 resistance

—

High glucose-induced PKCβ overexpression may reduce GLP-1 responsiveness in endothelial cellsPujadas 2016

Absolute Contraindications

Chonluten

·Known hypersensitivity to peptide components

GLP-1 (7-37)

—

Relative Contraindications

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

GLP-1 (7-37)

—

05Administration Protocol

Parameter

Chonluten

GLP-1 (7-37)

1. Preparation

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

Native GLP-1(7-37) is not formulated for therapeutic use. Administered IV or SC in experimental protocols to study GLP-1R pharmacology and as reference standard for analogue development.

2. Oral route

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

Lyophilised peptide stored at -20°C or below. Reconstituted solutions should be prepared fresh and used immediately due to rapid degradation.

3. Sublingual route

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

For therapeutic GLP-1R activation, use FDA-approved long-acting analogues: semaglutide (once weekly), liraglutide (once daily), dulaglutide (once weekly), or exenatide (twice daily or once weekly).

4. Timing

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

—

5. Cycle protocol

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.

—